US-based clinical research software company Ryght AI has partnered with Cancer Research South Australia (CRSA) to advance cancer clinical trials and expand patient access to new treatments.

As part of the collaboration, CRSA will become part of the Ryght Research Network, utilising Ryght AI’s technology for expediting and optimising trials.

By combining Ryght AI’s AI-driven solutions with CRSA’s ‘expertise’ in cancer trials, the collaboration aims to simplify trial processes, decrease administrative burdens and connect subjects in South Australia with new treatments.

With the inclusion of CRSA, the Ryght Research Network will employ generative AI technology to offer instantaneous insights, aiming to help research sites make data-led decisions while upholding data security standards.

Ryght AI CEO Simon Arkell said: “We are excited to welcome CRSA to the Ryght Research Network.

“Their commitment to providing state-of-the-art cancer care aligns perfectly with our mission to revolutionise clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Enter your work email
First Name
Last Name
Company Name
Job title *
Phone number *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“By leveraging our AI technology, we aim to help CRSA accelerate patient access to novel cancer therapies and further establish clinical trials as the gold standard choice for cancer treatment.”

The collaboration is intended to alter traditional trial workflows with the automation of essential tasks such as selection and activation of sites, feasibility assessments, subject referrals, and selecting the study, thereby expediting subject enrolment as well as trial management.

Ryght AI’s site technology will be implemented at CRSA, integrating with CRSA’s current Xestro Electronic Medical Records and RealTime Clinical Trial Management systems.

CRSA director and medical oncologist Rohit Joshi said: “Partnering with Ryght AI marks a significant milestone in expanding access to innovative clinical trials.

“By incorporating Ryght’s AI-driven solutions into our workflows, we aim to enhance operational efficiency, elevate patient care, and ultimately achieve better outcomes for cancer patients throughout South Australia.”

Earlier this month, Ryght AI began a strategic collaboration with QPS Holdings to optimise clinical trial processes on a global scale.